Assessment of Early Genetic Changes in Smokers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00200408|
Recruitment Status : Terminated (unable to obtain funding)
First Posted : September 20, 2005
Last Update Posted : April 8, 2015
|Condition or disease|
|Cancer of Head and Neck Smoking|
Our pilot study using cellular DNA (cDNA) microarrays to examine the buccal mucosa of smokers and non-smokers demonstrated that smokers could be separated from non-smokers based solely on the patterns of gene expression observed. We were able to identify 924 genes whose expression differs significantly between samples from smokers and non-smokers. Several genes were also shown to be either up or down regulated in our earlier research applying microarray analysis to head and neck cancer tumors. Many of these represent genes of possible interest as early molecular markers for head and neck carcinogenesis.
Aberrant methylation is an important event in the transcriptional silencing of candidate tumor suppressor genes in smoking associated malignancies. Furthermore, it is known that methylated CpG islands are the preferred binding site for benzo(a)pyrene diol epoxide and other carcinogens found in tobacco smoke. Binding of these compounds is known to cause DNA adducts and transversion mutations that are often observed in the aerodigestive tumors of smokers. New evidence suggests that specific DNA methylation events are directly linked to tobacco use. The ability to detect such molecular markers during screening of high risk groups would represent a significant advance in cancer screening and early detection. Our group has evaluated specimens to epigenetically profile CpG island hypermethylation in. head and neck squamous cell carcinoma ( HNSCC) tumor samples using a technique known as methylation specific restriction enzyme microarray analysis. This method will be used in this trial to detect alterations in global DNA methylation patterns in subjects who smoke compared to those who don't.
The objectives of this study are:
- Test the hypothesis that there are specific genetic alterations, leading to gene expression profile changes, which will be detected in early smokers.
- Test the hypothesis that early smokers will demonstrate alterations in global DNA methylation patterns compared to matched controls.
- To analyze gene alterations and DNA methylation in college smokers over time through longitudinal follow-up.
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Observational Model:||Case Control|
|Official Title:||Assessment of Early Genetic Changes in Smokers|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||January 2005|
college students who smoke
college students who don't smoke
- alteration of gene expression profile [ Time Frame: 2 yrs ]comparison of gene expression profiles between smokers and non-smokers
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00200408
|United States, New York|
|Montefiore Medical Center|
|Bronx, New York, United States, 10467|
|Study Chair:||Richard V Smith, MD||Montefiore Medical Center|
|Principal Investigator:||Thomas Belbin, PhD||Albert Einstein College of Medicine, Inc.|
|Principal Investigator:||Nicholas Schlecht, PhD||Albert Einstein College of Medicine, Inc.|